{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:30:00Z","timestamp":1740133800579,"version":"3.37.3"},"reference-count":15,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"DOI":"10.1136\/archdischild-2018-315528","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T16:15:52Z","timestamp":1538064952000},"page":"archdischild-2018-315528","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Etanercept or adalimumab: which is a better biological therapy for juvenile idiopathic arthritis?"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5204-2371","authenticated-orcid":false,"given":"Harriet","family":"Hunter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"key-10.1136\/archdischild-2018-315528-1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"key-10.1136\/archdischild-2018-315528-2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.1136\/archdischild-2018-315528-3","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2012-201991","article-title":"Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons","volume":"72","author":"Otten","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key-10.1136\/archdischild-2018-315528-4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20340","article-title":"The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation","volume":"20","author":"Shepherd","year":"2016","journal-title":"Health Technol Assess"},{"key":"key-10.1136\/archdischild-2018-315528-5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.semarthrit.2016.07.001","article-title":"Biological agents in polyarticular juvenile idiopathic arthritis: a meta-analysis of randomized withdrawal trials","volume":"46","author":"Amarilyo","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"key-10.1136\/archdischild-2018-315528-6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","article-title":"Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab","volume":"18","author":"Horneff","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"key-10.1136\/archdischild-2018-315528-7","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1007\/s10067-016-3439-y","article-title":"Safety and efficacy of etanercept and adalimumab in children aged 2 to 4\u00a0years with juvenile idiopathic arthritis","volume":"35","author":"Windschall","year":"2016","journal-title":"Clin Rheumatol"},{"key":"key-10.1136\/archdischild-2018-315528-8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/cei.12782","article-title":"The impact of disease activity and tumour necrosis factor-\u03b1 inhibitor therapy on cytokine levels in juvenile idiopathic arthritis","volume":"184","author":"Walters","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"key-10.1136\/archdischild-2018-315528-9","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/rheumatology\/ket170","article-title":"Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?","volume":"52","author":"Anink","year":"2013","journal-title":"Rheumatology"},{"key":"key-10.1136\/archdischild-2018-315528-10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00296-014-3103-2","article-title":"Efficacy and safety of TNF-alpha antagonists in children with juvenile idiopathic arthritis who started treatment under 4 years of age","volume":"35","author":"Gim\u00e9nez-Roca","year":"2015","journal-title":"Rheumatol Int"},{"key":"key-10.1136\/archdischild-2018-315528-11","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.1136\/archdischild-2018-315528-12","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis","volume":"77","author":"Quartier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key-10.1136\/archdischild-2018-315528-13","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1097\/MIB.0000000000000037","article-title":"Pharmacokinetics of adalimumab in inflammatory bowel diseases","volume":"20","author":"Paul","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key-10.1136\/archdischild-2018-315528-14","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1007\/s10620-015-4007-z","article-title":"Inflammatory bowel disease provoked by etanercept: report of 443 possible cases combined from an IBD Referral Center and the FDA","volume":"61","author":"O\u2019Toole","year":"2016","journal-title":"Dig Dis Sci"},{"key":"key-10.1136\/archdischild-2018-315528-15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3899\/jrheum.140102","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2018-315528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T22:14:16Z","timestamp":1601072056000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2018-315528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":15,"alternative-id":["10.1136\/archdischild-2018-315528"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2018-315528","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"type":"print","value":"0003-9888"},{"type":"electronic","value":"1468-2044"}],"subject":[],"published":{"date-parts":[[2018,9,27]]}}}